A new horizon for the old antibacterial drug clofoctol.
Drug Discov Today
; 26(5): 1302-1310, 2021 05.
Article
in English
| MEDLINE | ID: covidwho-1077854
ABSTRACT
The synthetic antibacterial drug clofoctol (CFT) has long been used to treat respiratory tract infections in Europe. In recent years, the drug was found to target two biologically important proteins, the Cdc7/Dbf4 protein kinase complex and the mRNA-binding protein cold shock domain containing E1 (CSDE1), also known as upstream-of-N-Ras protein (UNR). These interactions are at the origin of the antitumor activity of CFT, recently evidenced in prostate cancer and neuroglioma. Drug-protein binding models provide a structural basis to guide the design of more potent anticancer compounds. A renewed interest in CFT can be anticipated for the treatment of cancers, and possibly Coronavirus 2019 (COVID-19).
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Drug Repositioning
/
COVID-19 Drug Treatment
/
Anti-Bacterial Agents
/
Neoplasms
/
Antineoplastic Agents
Limits:
Animals
/
Humans
Language:
English
Journal:
Drug Discov Today
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS